TY - JOUR
T1 - Epidemiology research to foster improvement in chronic kidney disease care
AU - Luo, Shengyuan
AU - Grams, Morgan E.
N1 - Funding Information:
MEG and SL are supported by the National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases ( R01 DK108803 ).
Publisher Copyright:
© 2019 International Society of Nephrology
PY - 2020/3
Y1 - 2020/3
N2 - With the increasing availability of linked electronic health records, long-running cohorts, and high-throughput technologies, the potential for epidemiology research to improve the care of patients with kidney disease is greater than ever before. In this review, we highlight the application of epidemiology techniques to identify, evaluate, and address chronic kidney disease. We discuss studies that inform guidelines, identify health disparities, evaluate the genetic basis of disease, and relate data on omics, such as proteomics, metabolomics, and genetics, to outcomes. We describe how observational data have been used to facilitate the conduct of randomized controlled trials through enhanced identification of high-risk individuals and the evaluation of surrogate kidney disease outcomes as well as to address clinical questions where randomized controlled trials are impractical or infeasible. Finally, we discuss consumer engagement in research, including that of patients, policymakers, payers, and health care system, and the role of kidney disease epidemiology research in implementation science and as a key source of data and methodology for precision medicine.
AB - With the increasing availability of linked electronic health records, long-running cohorts, and high-throughput technologies, the potential for epidemiology research to improve the care of patients with kidney disease is greater than ever before. In this review, we highlight the application of epidemiology techniques to identify, evaluate, and address chronic kidney disease. We discuss studies that inform guidelines, identify health disparities, evaluate the genetic basis of disease, and relate data on omics, such as proteomics, metabolomics, and genetics, to outcomes. We describe how observational data have been used to facilitate the conduct of randomized controlled trials through enhanced identification of high-risk individuals and the evaluation of surrogate kidney disease outcomes as well as to address clinical questions where randomized controlled trials are impractical or infeasible. Finally, we discuss consumer engagement in research, including that of patients, policymakers, payers, and health care system, and the role of kidney disease epidemiology research in implementation science and as a key source of data and methodology for precision medicine.
KW - chronic kidney disease
KW - consumer engagement
KW - epidemiology research
KW - implementation science
KW - omics research
UR - http://www.scopus.com/inward/record.url?scp=85078221670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078221670&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2019.11.010
DO - 10.1016/j.kint.2019.11.010
M3 - Review article
C2 - 32001066
AN - SCOPUS:85078221670
VL - 97
SP - 477
EP - 486
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 3
ER -